Bionomics and GTG announce strategic alliance to jointly commercialise new genetic tests for epilepsy.Bionomics bi·o·nom·ics n. (used with a sing. verb) See ecology. [From French bionomique, pertaining to ecology, from bionomie, ecology : Greek bio-, bio- Limited (Australia) and Genetic Technologies Limited (Sydney, Australia) formed a strategic alliance to commercialise new genetic tests for epilepsy. These new diagnostic tools enable earlier diagnosis, more precise treatment and better overall outcomes for those suffering from inherited forms of epilepsy. Under the alliance, Bionomics grants to GTG (chat) gtg - Got to go. The user is about to stop chatting. worldwide testing and marketing rights, including exclusivity for Australia and New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. , to new epilepsy tests developed by Bionomics. GTG now grants to Bionomics a license to the GTG non-coding patents. The first test to be launched under this programme will identify cases of severe myoclonic epilepsy Myoclonic epilepsy refers to a family of epilepsies which present with myoclonus. They are divided into two main families:
SMEI Sony Music Entertainment Inc. SMEI Severe Myoclonic Epilepsy of Infancy SMEI Small/Medium Enterprise Initiative ) - a serious form of epilepsy in children. The tests will be performed by GTG and will also be made available to the GENDIA network of international genetic testing Genetic Testing Definition A genetic test examines the genetic information contained inside a person's cells, called DNA, to determine if that person has or will develop a certain disease or could pass a disease to his or her offspring. laboratories, which will bring these tests to more than 70 countries around the world, including key markets in United States and Europe. Bionomics and its academic collaborators will support GTG in the development and marketing of these tests. A key benefit of the SMEI test will be faster and more definitive diagnosis of this serious condition, thereby helping to guide treatment options. Additional tests in relation to other causes of epilepsy will be added to the programme in due course. The precise terms of the financial arrangements between GTG and Bionomics are covered by confidentiality, but it can be disclosed that both parties will benefit from the revenues generated from this new alliance. GTG will pay Bionomics a signing fee, royalties and future milestone payments in relation to revenues received from this epilepsy testing, world-wide, while Bionomics will also pay GTG for a license to the GTG non-coding patents. Bionomics holds patent applications at various stages of prosecution incorporating over 600 genes it has discovered and related utility in specific therapeutic and diagnostic applications. The company is leveraging that expertise and intellectual property to generate both near term and longer-term revenues. Focusing on central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency (particularly epilepsy) and cancer, Bionomics and its collaborative partners are developing diagnostics for the early detection of these conditions (near term revenue) and therapeutics to treat them (longer term revenue). The company is looking to generate growth both organically and through acquisition. Bionomics' drug and diagnostic development is built on two proprietary discovery platforms. IonX, is used to identify genetic targets for potential diagnostics and therapeutics for epilepsy and Angene is used to identify angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. based cancer drug prospects. Bionomics Limited +61 8 8354 6101 www.bionomics.com.au |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion